Unravelling Sex Differences in the Genetic Architecture of Anxiety: A Genome-Wide Association Study in the UK Biobank

Jihua Hu[1,2], Michelle K. Lupton[1,2,3], Enda M. Byrne[4], Nicholas G. Martin[1], David C. Whiteman[2,5], Catherine M. Olsen[2,5], Jodi T. Thomas[1,2], Sarah E. Medland[1,6,7], Katrina L. Grasby[1,2,3#], Brittany L. Mitchell[1,2,3#]

[1] Brain and Mental Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
[2] Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia
[3] School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia
[4] Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia
[5] Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
[6] School of Psychology, The University of Queensland, Brisbane, QLD, Australia
[7] School of Psychology and Counselling, Queensland University of Technology, Brisbane, QLD, Australia
# equally contributing

Corresponding author: Dr Brittany Mitchell, brittany.mitchell@qimrb.edu.au

Running title: Sex Differences in the Genetics of Anxiety

Keywords: Anxiety, Sex Differences, Genome-wide association study, Polygenic risk scores, Sex-linked, Genetics

Word count: 4053

Abstract

Background: Anxiety disorders show striking sex differences in prevalence, symptoms, and clinical characteristics, shaping how they manifest and are experienced.

Methods: This study investigated the genetic basis of these differences using sex-specific genome-wide association studies (GWAS). GWAS were conducted separately in females (47,054 cases, 57,027 controls) and males (23,819 cases, 55,030 controls) within the UK Biobank. Functional annotation, sex-specific polygenic scores (PGS), and genetic correlations were performed to assess genetic differences and functional implications.

Results: In females, 10 lead SNPs were significantly associated with anxiety, compared to four in males. Among these, three lead SNPs in females and two in males demonstrated significantly different effect sizes across sexes. In addition, SNP-based heritability estimates were significantly different and gene-based tests and functional prioritization identified different genes associated with anxiety in females and males. However, whole-genome analyses, including genetic correlations across sexes and PGS predictions, revealed no significant genetic differences between the sexes. Sex combined GWAS of several traits showed a trend toward sex differences with anxiety in genetic correlation analysis. Sex-specific GWAS on waist-to-hip ratio (WHR) adjusted for BMI enabled separate genetic correlation analyses with anxiety, revealing significant sex differences that were not observed in the combined GWAS.

Conclusions: This study is the first sex-specific GWAS of anxiety. While the overall genetic architecture of anxiety is largely shared between sexes, our findings reveal distinct sex-specific genetic associations and correlations, highlighting the value of analysing the sexes separately to uncover genetic signals that may be masked in sex-combined samples.

Introduction

Anxiety disorders are the most common mental health disorders in the world, and a leading cause of disability-adjusted life years lost. Approximately one-third of individuals may have an anxiety disorder in their life, and an increasing number of individuals are seeking help and treatment. Consequently, these disorders pose a substantial burden on public health systems globally (1).

Anxiety disorders form a group of mental health conditions characterized by excessive fear and worry. These include specific phobias, such as fear of spiders or heights; social anxiety, where individuals are anxious about social interactions; agoraphobia, marked by fear of open spaces and being alone outside; panic disorder, characterized by persistent fear of having future panic attacks; and generalized anxiety disorder (GAD), which involves pervasive anxiety about various aspects of life (2). Though diagnostically distinct, the key feature among these disorders is consistent: individuals overestimate the danger and have uncontrolled fear or worry.

There are notable differences between females and males in the prevalence of anxiety disorders, with females being about twice as likely to be affected as males. The prevalence difference between sexes has been consistently observed in specific anxiety disorders and across different cultures (3), and when all anxiety disorders are grouped together, the 2:1 prevalence ratio persists (4). Males and females also tend to manifest anxiety differently, with females commonly reporting more internalizing symptoms and comorbid depression, while males are more likely to exhibit externalizing symptoms and are more prone to substance use (3,5). Few studies have investigated the mechanisms underlying these sex differences in anxiety, primarily using rodent models, and examining psychosocial factors in human studies (5). However, the specific mechanisms underlying these sex differences remain largely unknown and warrant further investigation.

Genetic variation contributes moderately to anxiety disorders, with heritability estimated between 30% and 50% from twin studies (6). Both twin studies (7,8) and genome-wide association studies (GWAS) suggest a considerable shared genetic liability among different anxiety disorders. Therefore, shared genetics play a non-negligible role across all anxiety disorders, highlighting the potential for studying them as a collective group.

The role that genetic factors play in sex differences in anxiety disorders has been studied through twin studies, but the findings have been mixed. For instance, there is evidence that girls exhibit higher heritability than boys in anxiety symptoms (9) and separation anxiety (10). Additionally, genetic differences contribute to sex differences in the assessment of both depression and anxiety (11), and Burton et al. (12) noted that a model that included anxiety-specific genetic factors provided the best fit in females with comorbid depression but not in males. However, Burton's study found no sex differences in the overall magnitude of genetic influence when studying depression or anxiety separately, and other studies have reported minimal influence of genetics in sex differences in anxiety (7,13).

Previous GWAS have identified up to 51 loci associated with this complex trait (14–18), however, none of them have focused on sex heterogeneity. We conducted the first sex-specific GWAS for anxiety to directly explore whether common genetic factors contribute to sex

differences in anxiety. By examining sex-specific genetic associations with anxiety, we can investigate the molecular underpinnings of sex differences in anxiety disorders.

Methods and Materials

Study Population:

All participants were drawn from the UK Biobank, which is a large nationwide cohort recruited across 22 centers in the UK from 2006, consisting of 488,377 genotyped individuals between the age of 40 to 69 (19). We excluded individuals without genotype information, those with mismatched self-reported and genetic sex, and those who withdrew consent. This study used data from participants that were classified as white British within the UK Biobank data (20).

In this study, we identified participants who met DSM-5 criteria for the following anxiety disorders (2): agoraphobia, social phobias, specific phobias, generalized anxiety disorders, panic disorders and other phobic anxiety disorders. Lifetime anxiety cases and controls were defined according to criteria detailed in Figure 1 and supplementary methods. This resulted in a final sample of 70,873 cases and 112,057 controls (Females 47,054 cases, 57,027 controls; Males 23,819 cases, 55030 controls)

Genome-wide association analyses

Genome-wide association studies were performed using REGENIE (v 2.2.4) (21). Logistic regressions were conducted on chromosomes 1 to 23 in a combined sample, as well as in females and males separately. We assumed complete dosage compensation in females for testing associations of anxiety and variants in the non-pseudoautosomal region of chromosome X (genotypes in males were coded as 0/2). For the sex-specific analyses, we adjusted for the genotype array and the first four genetic principal components (PCs). For the combined GWAS we additionally adjusted for genetic sex. Genetic variants with a minor allele frequency less than 0.5% and imputation quality score less than 0.6 were excluded from association test results.

Characterisation of loci, functional annotation, and gene-based testing

To identify trait-associated variants within LD blocks, we defined lead SNPs as those with $r^2 < 0.1$ and $P < 5\times10^{-8}$ using FUMA(v1.6.1) (22).

Lead SNPs and their proxies ($r^2 \geq 0.6$) were annotated in FUMA to prioritize genes, excluding the major histocompatibility complex region:

1. Positional mapping that mapped SNPs to genes within 10 kb;
2. eQTL mapping used data from the Brain eQTL Almanac (Braineac), GTEx V8 brain and adrenal gland datasets, focusing on significant eQTLs (FDR ≤ 0.05). The adrenal gland was included due to its role in the fight-or-flight response (23);
3. Chromatin interactions were mapped using all available Hi-C data in FUMA (FDR <= 1×10^{-6}).

MAGMA (Multi-marker Analysis of GenoMic Annotation) in FUMA was used for gene-based, gene-set, and gene-expression association tests. Gene-based association, tested with the SNP-wise mean model, included SNPs within 2 kb upstream and 1 kb downstream of genes,

with Bonferroni-corrected significance set at $P<2.493\times10^{-6}$. Gene-set analysis explored shared biological functions using curated gene sets and gene ontology (GO) terms from MSigDB(v2023.1). Gene-expression analysis tested tissue-specific expression of associated genes using GTEx V8 data across 54 and 30 tissue types.

We further examined SNPs that were significantly associated with at least one sex. For SNPs that were significant in both sexes and located on the same chromosome, we checked how closely these SNPs were linked through LD link (24). For SNPs that were significant in one sex but not in the other, we retrieved the corresponding SNP from the opposite sex's GWAS result, and then explored the association of SNPs within 500 kb around this significant SNP by visually inspecting LocusZoom plots (25) to determine if there was a signal that was sub-threshold to genome-wide significance.

Heritability and genetic correlations

SNP-based heritability was estimated using LD Score Regression (LDSC) (v1.0.1) (26). Heritability estimates were converted to the liability scale based on the NIH's estimated prevalence of anxiety: 19.1% overall, 23.4% in females, 14.3% in males (27). The LDSC intercept was used to check for inflation due to confounding from cryptic relatedness or population stratification.

We investigated the genetic correlation between sex-specific anxiety and anxiety associated traits using LDSC, including mental health conditions, gastrointestinal symptoms, substance use, metabolism, some social behaviors, and sex hormones. Where available, we used both combined and sex-specific GWASs. All p-values were adjusted for FDR using the Benjamini-Hochberg approach. To determine significant differences between female- and male-specific genetic correlation with each trait, we calculated a Z-score as the difference between the sex-specific genetic correlations divided by the sum of the squares of their respective standard errors, and a two-tail p-value from the Z-score (28); the corresponding adjusted P-value was computed using the BH method (29).

Polygenic scores

To test whether our results were able to significantly predict anxiety in independent samples, we calculated polygenic scores (PGS) using SBayesR (30). SBayesR is a Bayesian technique that estimates the effect of SNPs from multi-normal distributions which may reflect the true distribution of genetic variants. The estimated PGS were standardized using the *scale()* function in R(v4.2.0).

We tested the association of PGS derived from our GWAS results with case-control lifetime anxiety status and current anxiety symptoms (GAD-7) in two population cohorts (QSkin (31) and PISA (32) respectively), as well as a large clinical, comorbid-depression cohort (Australian Genetics of Depression Study; AGDS (33)) (**Supplementary Methods, Table 1**). While larger in size, it is important to note that in AGDS all the anxiety cases have comorbid depression. Therefore, this sensitivity analysis may distinguish prediction between population-based, non-comorbid cohorts and clinical, comorbid-depression cohorts. To control for potential familial relationships, we conducted a restricted maximum likelihood (REML) analysis using GCTA(v1.91.7) (34), adjusting for the first 10 PCs and sex (combined analysis only).

To examine whether our PGS results were influenced by differences in sample sizes, and thus statistical power, across our discovery GWASs, we downsampled the number of cases and controls in the female-specific GWAS to match those in the male-specific GWAS, while maintaining the original 2:1 female-to-male ratio. This was done through random selection using the *sample()* function in R(v4.2.0). We then repeated the above regression analyses using these downsampled results.

Results

GWAS of lifetime anxiety disorders in the total sample

We conducted a GWAS on 182,930 individuals for lifetime anxiety, identifying 21 lead SNPs (**Table S2 and Figure 2A**) associated with anxiety. Among these, five SNPs were in LD ($r^2 > 0.8$ or D' > 0.95) with variants reported by previous anxiety studies (16,17). The LDSC intercept of 1.03 (SE = 0.01), indicated minimal inflation from population stratification (**Table S3**). Heritability on the liability scale was 0.12 (SE = 0.01), assuming a population prevalence of 0.19.

Sex-specific GWASs of anxiety disorders

Sex-specific GWAS analyses were performed using 104,081 females and 78,849 males. A total of 10 and 4 lead SNPs were identified in the female- and male-specific GWAS, respectively (**Table S4, S5** and **Figure 2B**). The strongest association in females was rs2145318 on chromosome 6, and in males was rs7069805 on chromosome 10. Notably, no overlapping significant SNPs were found between females and males.

We further explored the effect sizes of the 14 lead SNPs from the sex-specific GWASs (**Figure 3**), allowing for a direct comparison of their influences in females and males. Five out of the 14 lead SNPs showed a clear separation, as their 95% confidence intervals did not overlap, suggesting a statistically significant difference in their effect sizes. Among these five SNPs, three were significantly associated with female anxiety: rs98778806 (nearest gene: *ZBTB20*), rs34210476 (nearest gene: *AC020952.1*), and rs2145318 (nearest gene: *BTN3A1*). The remaining two SNPs were significantly associated with male anxiety: rs7069805 (nearest gene: *NEBL*) and rs11780074 (nearest gene: *RP11-120I21.2*).

The LDSC intercepts of the female and male GWAS were 1.02 (0.008) and 1.02 (0.007) respectively, suggesting minimal confounding effects in the GWAS results (**Table S3**). The heritability on the liability scale was estimated at 0.15 (0.01) for females and 0.12 (0.01) for males, with the difference being statistically significant (Z-score = 2.12, p = 0.03). The genetic correlation between females and males was not significantly less than unity (rg = 0.94, se = 0.05, 95% CI: 0.84, 1.04).

Follow up investigations of significant SNPs across sexes

Chromosome 19 was the only chromosome with SNPs significantly associated with lifetime anxiety in both male- and female-specific GWAS, with an R^2 of 0.0001, indicating no LD between them. For SNPs significant in only one sex, we retrieved the corresponding SNP from the other GWAS and inspected surrounding variants using locus zoom plots (**Figures S1, S2**). No variants in the same LD structure had p-values below 1×10^{-4} in the opposite sex. While some signals in one sex appeared mirrored in the other (e.g., chromosome 18; **Figure 2B**), further analysis confirmed they were not in the same LD block.

Gene-level analysis

To explore the genes likely to be associated with lifetime anxiety, we first prioritized genes through FUMA. A total of 276, 179 and 45 prioritized genes were identified from the combined, female- and male-specific GWAS respectively (**Tables S6-S8**). Among the 276 prioritized genes from the combined GWAS, 39 were also prioritized in males and 141 were prioritized in females. We also tested the association of genes through MAGMA. We found 31, 19 and 6 genes passed the significance threshold from combined, female- and male-specific GWAS respectively (**Tables S9-S11**). All 19 genes identified in the female GWAS through MAGMA, along with four out of the six genes from the male GWAS, were also present in the combined GWAS. Notably, there was no overlap of either prioritized or MAGMA genes between females and males (**Figure 4**). The metabolism related genes *B3GLCT* and *APOC1* were both prioritized by FUMA and significant in MAGMA in males, but showed no association in females. There are 14 genes that have been highlighted by both MAGMA and FUMA prioritization in females, including butyrophilin subunit coding genes, which is an immune symptom regulator; histone related genes; a transcription factor protein *HMGN4*, and *FOXP2*.

In both females and males, SNPs were significantly enriched for gene expression in brain tissues, such as the hypothalamus, as identified by MAGMA gene-based analysis (**Tables S12, S13**). Gene-based scores from females were associated with 15 gene ontology (GO) biological processes of chromatin regulation related gene sets, and olfactory transduction involved gene sets, while genes-based scores in males were associated with three GO terms related to lipoprotein clearance and efflux (**Table S14**).

Polygenic Score Associations

Our combined anxiety disorder GWAS derived PGS_C showed strong association with self-reported lifetime anxiety in individuals in the QSkin cohort (R^2 = 1.30% and P = 2.04×10^{-44}). When examining prediction of sex-specific PGS, larger sample sizes corresponded to better predictive values, with the original PGS_C showing the best prediction in both females and males, followed by PGS_F for predicting both groups (**Figure 5, Table S15**). To exclude the potential influence of PGS derived from GWAS with differing power on the predictive ability, we downsized the GWAS for females and the combined sample to match that of males (**Figure S3**). The downsized-PGS_C showed a similar significant, albeit attenuated, association with anxiety ($R^2_{downsized}$ = 0.61%, $P_{downsized}$ = 9.34×10^{-22}, **Figure 5A**). For females, the downsized PGS_F (R^2=0.98%) showed the best predictive value compared to both downsized PGS_C (R^2 = 0.76%) and PGS_M (R^2 = 0.35%). For males, the downsized PGS_F (R^2 = 0.81%) showed the best predictive ability again, followed by PGS_C (R^2 = 0.47%) and then the PGS_M (R^2 =0.39%). However, these differences were not statistically significant and the findings in males exhibit large overlapping confidence intervals between PGSc, PGS_F and PGS_M.

Both original and downsized PGS_C showed the strongest prediction of current levels of anxiety using the GAD-7 score in PISA (R^2 = 1.10%, P = 1.55×10^{-12} and R^2= 0.41%, P = 1.50×10^{-5} , respectively) (**Table S16**). When examining predictions in each sex (**Figure 5B**), the original PGS_C showed the best predictive value in females and males, followed by the original PGS_F and then PGS_M. For downsized GWAS derived PGSs, PGS_F predicted slightly more variance in females (R^2_F = 0.56%), followed by PGS_C (R^2_C = 0.23%), and then PGS_M (R^2_M = 0.27%). In males, the downsized PGS_C resulted in the largest estimate (R^2_C = 1.00%), followed by PGS_F

(R^2_F =0.77%), and then by PGS_M (R^2_M = 0.73%). As with the lifetime anxiety, these small differences in predictive value were not statistically significantly different.

Lastly, we tested the PGS associations in a depression cohort (**Table S17, Figure S4A**). The trend of the predictive ability of the original PGS was consistent with the QSkin and PISA cohorts. Once downsized, there was no difference in the performance of the PGS derived from the combined, the female-specific, or the male-specific GWAS when predicting into either sex. For the prediction of current levels of anxiety, one difference between the AGDS cohort, where cases have comorbid depression, and the PISA cohort was that none of the PGS_M predictors were significant, nor were any PGS significant when predicting GAD-7 in AGDS males (**Table S18, Figure S4B**).

Sex-specific genetic correlations

The genetic correlation between our lifetime anxiety GWAS and the previous Purves et al.,(16) anxiety GWAS in UKB was rg = 0.93 ($P < 1\times10^{-300}$), and a recent GWAS of anxiety factors (37) was rg = 0.73 ($P < 1\times10^{-300}$), indicating significant genetic overlap and supporting the reliability of our GWAS results.

In addition to genetic correlations with other anxiety studies, our analysis revealed that 20 out of the 26 tested traits demonstrated significant genetic correlation ($P_{FDR} < 0.05$) for both female- and male-specific anxiety GWAS results (**Figure 6, Table S19**). Notably, Inflammatory Bowel Disease (IBD) was not significantly associated with female-specific GWAS, but was significant in both the male-specific and combined GWAS.

No statistically significant sex differences were found in genetic correlations with tested traits, though some trends emerged. Females showed stronger genetic correlations with irritable bowel syndrome (IBS), metabolic syndrome, and body mass index (BMI), while males had higher correlations with inflammatory bowel disease (IBD) and waist-hip ratio (WHR) adjusted for BMI. For mental health traits, bipolar disorder—particularly bipolar II—had a stronger genetic correlation with anxiety in males. Both sexes showed a negative association with educational attainment, though it was stronger in females. No notable sex differences were observed for substance use measures.

Given the trend for sex differences in the genetic correlation between anxiety and WHR-adjusted BMI, we conducted sex-specific analyses using the available sex-specific WHR-adjusted BMI GWAS data (36). The genetic correlation between male anxiety and male WHR-adjusted BMI was 0.24 (SE = 0.04), compared to 0.13 (SE = 0.03) in females, a significant difference (Z = 2.4, P = 0.016).

Discussion

Our study set out to investigate the genetic basis of sex differences in anxiety disorders, marking a novel approach by leveraging GWAS and including the often-overlooked X chromosome. To our knowledge, this is the first study to comprehensively examine potential sex-specific genetic influences on anxiety disorders using this methodology.

Through sex-specific GWAS, we observed differences in significantly associated SNPs and annotated genes between females and males. Three female-specific and two male-specific lead SNPs showed statistically significant differences in effect size between the sexes. Among the female-specific lead SNPs: rs34214076 is novel; rs9878806 has been previously linked to Type

II diabetes (37), and rs2145318 has been specifically associated with gastroesophageal reflux disease (GERD) (38) and is in very high LD with a depression-associated SNP (39). The male-specific lead SNP, rs7069805 has been associated with pulse pressure (40) and smoking initiation (41), and rs11780074 has been linked to metabolic levels (42). These associations align with observed sex differences at the symptom level: females are more likely to have comorbid depression, while males are more likely to engage in substance use (3).

In addition to differences in specific SNPs, female- and male-stratified GWAS revealed completely distinct prioritized genes and corresponding biological processes. Genes prioritized in females were enriched in chromatin regulation and olfactory transduction, while genes prioritized in males were involved in regulation of lipoprotein levels. Chromatin regulation, including nucleosome remodeling, chromatin condensation, and histone methylation, influences gene expression and epigenetics (43). Histone modifications have been linked to anxiety, stress responses, and fear memory retrieval (43). The enrichment of chromatin interaction-related GO processes in females, but not males, may suggest greater environmental sensitivity. Olfactory function is associated with anxiety, depression, and other psychiatric conditions (44), with odor information primarily processed in the amygdala, a key stress-response region (45). Evolutionarily, olfaction aids threat detection, social communication, and survival. Higher anxiety levels have been linked to increased olfactory sensitivity (46), and women with anxiety report greater odor awareness than men (47), consistent with our findings that olfactory transduction-related genes are enriched only in females.

As for the male-specific enrichment in lipoprotein metabolism, both acute and chronic stress lead to elevated levels of lipoprotein in humans. This increase has been explained as a part of the body's response to provide energy for the fight-or-flight stress-coping mechanism (48). Higher lipoprotein levels have been found to be associated with depression in males (49), while females with higher lipoprotein levels were more likely to have lower scores on depression and anxiety tests (50). These differences may be due to the different lipoprotein metabolism in females and males, which is influenced by estrogen and testosterone-specific signaling pathways (51). The gene enrichment results suggest that genetic factors may contribute to these previously observed sex differences, offering a potential explanation in anxiety related pathways in females and males.

The genetic correlations between females and males were not significantly different from one, indicating no substantial sex differences. This finding does not necessarily conflict with our observation of sex differences at the locus and gene level, as the distinct effects of a few SNPs and prioritized genes may be diluted when assessed at the whole-genome level. However it does indicate that despite some small differences between females and males, the genetic influences on developing anxiety are largely the same.

The findings from the PGS analyses were consistent with the genetic correlations. There was no significant difference in prediction after downsizing the female and combined samples to be equivalent in size to that available on males. The stronger predictive ability evident from our tests using the full sample appears to be due to a larger sample size. There was a trend for the downsized PGS_F to have a stronger prediction in females in the population-based cohort, which may emerge as significant with a stronger PGS instrument and a larger target sample size. However, this trend was not evident in the much larger target sample of individuals with comorbid depression, thus may be a sampling effect. These PGS analyses generally indicate

that when considering genetic influences across the genome on anxiety, they are comparable in predictive ability.

We explored sex-specific genetic correlations with other traits, finding some traits more strongly correlated with one sex. The relationship between IBS and anxiety has been well-documented (52), with females more likely to experience both, potentially due to sex differences in stress response systems (53). IBD is a strongly related gastrointestinal trait that includes Crohn's disease and ulcerative colitis but was not significantly associated with female-anxiety in our study. This may be due to sex differences in presentation (females more likely to develop Crohn's disease, males ulcerative colitis) or genetics (54). Current IBD GWAS data primarily focuses on ulcerative colitis, which is more common in males (55).

Bipolar disorders, characterized by alternating manic and depressive episodes, showed a higher genetic correlation with anxiety in type II (depressive episodes are predominant) than type I bipolar disorder (distinguished by manic episodes). Furthermore, the correlation was higher in males across both subtypes, suggesting a sex-specific relationship between anxiety and bipolar disorder. Given that no consistent sex differences have been observed in bipolar disorder (56), our findings may offer a new perspective on the relationship between anxiety and bipolar disorder through a sex-specific approach.

When using a combined GWAS for WHR-adjusted BMI, the genetic correlation with anxiety was not significantly different between sexes. However, when using sex-specific GWAS, the correlation was significantly higher in males, indicating that sex-specific genetic contributions and their shared genetic basis with anxiety are obscured in the combined GWAS. The higher correlation in males may reflect sex-specific genetic and biological pathways, particularly those related to fat distribution, as indicated by WHR and enriched lipoprotein metabolism processes in the male-specific GWAS.

Overall, this study provides evidence of genetic sex differences in anxiety at both the SNP and gene levels, highlighting specific variants, prioritized genes, and enriched biological processes. However, these differences were not apparent when analyzing genome-wide associations. Standard GWAS often assume a shared genetic architecture across sexes, potentially masking sex-specific effects. Given that sex heterogeneity is common in complex traits, ignoring these differences may oversimplify the underlying biology. Future studies conducting sex-specific GWAS on a larger scale are essential for fully capturing the distinct genetic contributions to anxiety in males and females.

Limitations include the smaller male sample size, reducing statistical power compared to females. Larger samples may clarify sex differences or commonalities. Additionally, the UK Biobank sample is not representative of the general population, which may limit generalizability. Future sex-specific GWAS in other traits with known heterogeneity could enhance understanding of sex-specific genetic factors and shared genetic architecture across traits.

Acknowledgements

J.H was funded by a QIMR PhD scholarship. B.L.M (APP2017176), K.L.G (APP1173025), S.E.M (APP1172917 and APP2025674), and D.C.W (APP2026567) are supported by Investigator Grants from the National Health and Medical Research Council of Australia (NHMRC). E.M.B are supported by Research Excellence grant (1198304) from NHMRC Centre, and the University of Queensland Health Research Accelerator Program. The QSkin Study is supported by a Clinical Trials and Cohort Grant [APP1185416] from NHMRC. PISA was funded by an NHMRC Dementia Research Team Grant [APP1095227]. This study makes use of data from UK Biobank (Project ID: 25331).

We sincerely thank all UKB, AGDS, PISA and QSkin participants for their time and contributions to this study. We also appreciate everyone involved in the study's conception, implementation, media campaign, and data cleaning.

Disclosures

The authors declare no conflicts of interest.

Author contributions

J.H performed the analyses, wrote the manuscript and integrated input and feedback from all co-authors. B.L.M and K.L.G designed and supervised the study. Support and input was provided by S.E.M, who along with M.K.L, E.M.B, N.G.M, D.C.W, C.M.O were responsible for the cohort design, genotyping, and data acquisition, processing and quality control. J.T.T provided support with analyses. All authors read and approved the final manuscript.

References

1. Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022 Dec 27;328(24):2431–45.

2. Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed. Arlington, VA, US: American Psychiatric Publishing, Inc.; 2013. xliv, 947 p. (Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed).

3. McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender differences in anxiety disorders: Prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res. 2011 Aug 1;45(8):1027–35.

4. Yeretzian ST, Sahakyan Y, Kozloff N, Abrahamyan L. Sex differences in the prevalence and factors associated with anxiety disorders in Canada: A population-based study. J Psychiatr Res. 2023 Aug 1;164:125–32.

5. Farhane-Medina NZ, Luque B, Tabernero C, Castillo-Mayén R. Factors associated with gender and sex differences in anxiety prevalence and comorbidity: A systematic review. Sci Prog. 2022;105(4):368504221135469.

6. Craske MG, Stein MB, Eley TC, Milad MR, Holmes A, Rapee RM, et al. Anxiety disorders. Nat Rev Dis Primer. 2017 May 4;3(1):1–19.

7. Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS. The Structure of Genetic and Environmental Risk Factors for Anxiety Disorders in Men and Women. ARCH GEN PSYCHIATRY. 2005;62.

8. Tambs K, Czajkowsky N, Røysamb E, Neale MC, Reichborn-Kjennerud T, Aggen SH, et al. Structure of genetic and environmental risk factors for dimensional representations of DSM-IV anxiety disorders. Br J Psychiatry J Ment Sci. 2009 Oct;195(4):301–7.

9. Ask H, Torgersen S, Seglem KB, Waaktaar T. Genetic and environmental causes of variation in adolescent anxiety symptoms: a multiple-rater twin study. J Anxiety Disord. 2014 May;28(4):363–71.

10. Eaves LJ, Silberg JL, Meyer JM, Maes HH, Simonoff E, Pickles A, et al. Genetics and Developmental Psychopathology: 2. The Main Effects of Genes and Environment on Behavioral Problems in the Virginia Twin Study of Adolescent Behavioral Development. J Child Psychol Psychiatry. 1997;38(8):965–80.

11. Kendler KS, Heath AC, Martin NG, Eaves LJ. Symptoms of anxiety and symptoms of depression. Same genes, different environments? Arch Gen Psychiatry. 1987 May;44(5):451–7.

12. Burton KLO, Williams LM, Richard Clark C, Harris A, Schofield PR, Gatt JM. Sex differences in the shared genetics of dimensions of self-reported depression and anxiety. J Affect Disord. 2015 Dec 1;188:35–42.

13. Boomsma DI, Van Beijsterveldt CEM, Hudziak JJ. Genetic and environmental influences on Anxious/Depression during childhood: a study from the Netherlands Twin Register. Genes Brain Behav. 2005;4(8):466–81.

14. Otowa T, Hek K, Lee M, Byrne EM, Mirza SS, Nivard MG, et al. Meta-analysis of genome-wide association studies of anxiety disorders. Mol Psychiatry. 2016 Oct;21(10):1391–9.

15. Levey DF, Gelernter J, Polimanti R, Zhou H, Cheng Z, Aslan M, et al. Reproducible Genetic Risk Loci for Anxiety: Results From ∼200,000 Participants in the Million Veteran Program. Am J Psychiatry. 2020 Mar 1;177(3):223–32.

16. Purves KL, Coleman JRI, Meier SM, Rayner C, Davis KAS, Cheesman R, et al. A major role for common genetic variation in anxiety disorders. Mol Psychiatry. 2020 Dec;25(12):3292–303.

17. Friligkou E, Løkhammer S, Cabrera-Mendoza B, Shen J, He J, Deiana G, et al. Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study. Nat Genet. 2024 Oct;56(10):2036–45.

18. Li W, Chen R, Feng L, Dang X, Liu J, Chen T, et al. Genome-wide meta-analysis, functional genomics and integrative analyses implicate new risk genes and therapeutic targets for anxiety disorders. Nat Hum Behav. 2024 Feb;8(2):361–79.

19. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9.

20. MacGregor S, Ong JS, An J, Han X, Zhou T, Siggs OM, et al. Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma. Nat Genet. 2018 Aug;50(8):1067–71.

21. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat Genet. 2021 Jul;53(7):1097–103.

22. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017 Nov 28;8(1):1826.

23. Hinds JA, Sanchez ER. The Role of the Hypothalamus–Pituitary–Adrenal (HPA) Axis in Test-Induced Anxiety: Assessments, Physiological Responses, and Molecular Details. Stresses. 2022 Mar;2(1):146–55.

24. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015 Jul 2;31(21):3555.

25. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010 Jul 15;26(18):2336.

26. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015 Mar;47(3):291–5.

27. Any Anxiety Disorder - National Institute of Mental Health (NIMH) [Internet]. [cited 2024 Oct 29]. Available from: https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder

28. Blokland GAM, Grove J, Chen CY, Cotsapas C, Tobet S, Handa R, et al. Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biol Psychiatry. 2022 Jan 1;91(1):102–17.

29. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57(1):289–300.

30. Lloyd-Jones LR, Zeng J, Sidorenko J, Yengo L, Moser G, Kemper KE, et al. Improved polygenic prediction by Bayesian multiple regression on summary statistics. Nat Commun. 2019 Nov 8;10(1):5086.

31. Olsen CM, Green AC, Neale RE, Webb PM, Cicero RA, Jackman LM, et al. Cohort profile: the QSkin Sun and Health Study. Int J Epidemiol. 2012 Aug;41(4):929–929i.

32. Lupton MK, Robinson GA, Adam RJ, Rose S, Byrne GJ, Salvado O, et al. A prospective cohort study of prodromal Alzheimer's disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA). NeuroImage Clin. 2021 Jan 1;29:102527.

33. Byrne EM, Kirk KM, Medland SE, McGrath JJ, Colodro-Conde L, Parker R, et al. Cohort profile: the Australian genetics of depression study. BMJ Open. 2020 May 1;10(5):e032580.

34. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A Tool for Genome-wide Complex Trait Analysis. Am J Hum Genet. 2011 Jan 7;88(1):76.

35. Thorp JG, Campos AI, Grotzinger AD, Gerring ZF, An J, Ong JS, et al. Symptom-level modelling unravels the shared genetic architecture of anxiety and depression. Nat Hum Behav. 2021 Oct;5(10):1432–42.

36. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. Hum Mol Genet. 2019 Jan 1;28(1):166–74.

37. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. Diabetes. 2017 May 31;66(11):2888.

38. Ong JS, An J, Han X, Law MH, Nandakumar P, 23andMe Research team, et al. Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis. Gut. 2022 Jun;71(6):1053–61.

39. Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nat Neurosci. 2021 Jul;24(7):954–63.

40. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021 Oct;53(10):1415–24.

41. Saunders GRB, Wang X, Chen F, Jang SK, Liu M, Wang C, et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. Nature. 2022 Dec;612(7941):720–4.

42. Rhee EP, Ho JE, Chen MH, Shen D, Cheng S, Larson MG, et al. A Genome-Wide Association Study of the Human Metabolome in a Community-Based Cohort. Cell Metab. 2013 Jul 2;18(1):130.

43. Ell MA, Schiele MA, Iovino N, Domschke K. Epigenetics of Fear, Anxiety and Stress – Focus on Histone Modifications. Curr Neuropharmacol. 2023 Sep 1;22(5):843.

44. Marin C, Alobid I, Fuentes M, López-Chacón M, Mullol J. Olfactory Dysfunction in Mental Illness. Curr Allergy Asthma Rep. 2023 Mar 1;23(3):153–64.

45. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci. 2009 Jun;10(6):397–409.

46. Galliot E, Laurent L, Hacquemand R, Pourié G, Millot JL. Fear-like behavioral responses in mice in different odorant environments: Trigeminal versus olfactory mediation under low doses. Behav Processes. 2012 Jun 1;90(2):161–6.

47. Dal Bò E, Gentili C, Castellani A, Tripodi C, Fischmeister FPS, Cecchetto C. Olfactory meta-cognition in individuals with depressive and anxiety symptoms: The differential role of common and social odors. J Affect Disord. 2022 Jul 1;308:259–67.

48. Brindley DN, McCann BS, Niaura R, Stoney CM, Suarez EC. Stress and lipoprotein metabolism: Modulators and mechanisms. Metabolism. 1993 Sep 1;42(9, Supplement 1):3–15.

49. Bao J, Zheng S, Huang J, Xie X, Zhang J, Yang S, et al. Mental health is correlated with lipoprotein(a) levels in male patients with premature coronary heart disease. Ann Palliat Med. 2021 Jun;10(6):6482–92.

50. Suarez EC. Relations of trait depression and anxiety to low lipid and lipoprotein concentrations in healthy young adult women. Psychosom Med. 1999;61(3):273–9.

51. Palmisano BT, Zhu L, Eckel RH, Stafford JM. Sex differences in lipid and lipoprotein metabolism. Mol Metab. 2018 May 16;15:45.

52. Fond G, Loundou A, Hamdani N, Boukouaci W, Dargel A, Oliveira J, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014 Dec 1;264(8):651–60.

53. Kim YS, Kim N. Sex-Gender Differences in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018 Oct 1;24(4):544.

54. Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Ther Adv Gastroenterol. 2020 Apr 28;13:1756284820915043.

55. Wu Y, Murray GK, Byrne EM, Sidorenko J, Visscher PM, Wray NR. GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. Nat Commun. 2021 Feb 19;12(1):1146.

56. Diflorio A, Jones I. Is sex important? Gender differences in bipolar disorder. Int Rev Psychiatry. 2010 Oct;22(5):437–52.

Tables and Figures

Fig. 1: Schematic overview of case-control definition for lifetime anxiety in the UK Biobank. Cases were identified based on self-reported anxiety diagnosis, relevant hospital diagnoses, and diagnostic criteria while controls were defined as individuals without a history of mental health conditions.



Fig. 2: Scatter Plot of analyzed genetic variants for lifetime anxiety. A: Total sample (cases=70,873; controls=112057); B: Genetic variants in females (cases=47,054; controls=57,027) are plotted above the X-axis, those in males (cases=23,819; controls=55,030) are shown below the X-axis.



Fig. 3: Forest plot of effect sizes and 95% confidence intervals of lead SNPs from the sex-specific GWAS. The first section represents lead SNPs significantly associated with females, while the second section shows lead SNPs in males. Effect sizes for SNPs in females are represented in yellow, and those in males are shown in blue.



Fig. 4: Venn diagram of MAGMA identified and FUMA prioritized genes. F represents females, M represents males, and All represents combined GWAS. The colors for each set are indicated by the text labels, along with the number of genes in parentheses. There are 176 prioritized genes in females and 45 prioritized genes in males. MAGMA identified 19 genes significantly associated with females and 6 genes significantly associated with males. There are no overlapping genes between females and males.



Figure 5: Sex-Specific Polygenic Scores (PGS) in Lifetime Anxiety and GAD-7 4A: PGS prediction for anxiety status in females and males using the QSkin dataset 4B: PGS prediction for GAD-7 scores in females and males using the PISA dataset.

P-values for the beta coefficient are shown at the top of the 95% confidence interval bar. Bars in different colors represent PGS derived from different GWAS. To ensure comparability across PGS, the sample sizes of the original combined and female-specific GWAS were downsized to match that of the male-specific GWAS. Consequently, only the original male-derived PGS are presented in this figure.



Fig. 6: Forest plot of sex dependent genetic correlation. Values of genetic correlation (rg) are represented by circles and squares for females and males, respectively. The bars indicate the range of genetic correlation minus and plus the 95% confidence interval.



Tables

Table 1: Sex Distribution in Cohorts Used for Polygenic Score (PGS) Predictions

Cohort	**Measurement**	**Nfemales (cases/controls)**	**Nmales (cases/controls)**	**Ncombined (cases/controls)**
Qskin	Self-report	1,528/6,481	819/6,238	2,347/12,719
PISA	GAD-7	3,263	1,605	4,868
AGDS	Self-report	8,278/6,481	2,902/6,238	11,180/12,719
AGDS	GAD-7	5,556	1,681	7,282